HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways

Cancer Science

Volumn 102, Issue 2, 2011, Pages 393-399

  Nakabayashi, Hiromichi ^a   Shimizu, Keiji ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DNA BINDING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; GENE REPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ZYMOGRAPHY;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GLIOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 79952087218     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01794.x     Document Type: Article

References (41)

1. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-14.
2. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-4.
3. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 1999; 68: 459-86.
4. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-54.
5. Billadeau DD, Mackie SM, Schoon RA, Leibson PJ. The Rho family guanine nucleotide exchange factor Vav-2 regulates the development of cell-mediated cytotoxicity. J Exp Med 2000; 192: 381-92.
6. Shibuya M, Suzuki Y, Takayasu M et al. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs. Acta Neurochir 1988; 90: 53-9.
7. Ishizaki T, Uehata M, Tamechika I et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976-83.
8. Nakamura K, Nishimura J, Hirano K, Ibayashi S, Fujishima M, Kanaide H. Hydroxyfasudil, an active metabolite of fasudil hydrochloride, relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase. J Cereb Blood Flow Metab 2001; 21: 876-85.
9. Ikenoya M, Hidaka H, Hosoya T, Suzuki M, Yamamoto N, Sasaki Y. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem 2002; 81: 9-16.
10. Shibuya M, Suzuki Y, Sugita K et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992; 76: 571-7.
11. Kureishi Y, Kobayashi S, Amano M et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997; 272: 12257-60.
12. Aikawa R, Komuro I, Yamazaki T et al. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res 1999; 84: 458-66.
13. Yoshioka K, Matsumura F, Akedo H, Itoh K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 1998; 273: 5146-54.
14. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5: 221-5.
15. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001; 33: 577-81.
16. Benitah SA, Valerón PF, Lacal JC. ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell 2003; 14: 3041-54.
17. Yin L, Morishige K, Takahashi T et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007; 6: 1517-25.
18. Somlyo AV, Phelps C, Dipierro C et al. ROCK and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 2003; 17: 223-34.
19. Nakajima M, Hayashi K, Katayama K et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 2003; 459: 113-20.
20. Ying H, Biroc SL, Li WW et al. The ROCK inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006; 5: 2158-64.
21. Yang X, Liu Y, Zong Z, Tian D. The ROCK inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother 2010; 64: 58-62.
22. Deng L, Li G, Li R, Liu Q, He Q, Zhang J. ROCK inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 2010; 26: 875-84.
23. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 2009; 29: 119-23.
24. Klur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004; 70: 229-43.
25. Takahashi M, Fukami S, Iwata N et al. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol Res 2002; 46: 155-63.
26. Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol 2005; 15: 327-41.
27. Xu L, Fukumasa D, Jain RK. Acidic extracellular pH induces endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway. J Biol Chem 2002; 277: 11368-74.
28. Essafi-Benkhadir K, Pouysseegur J, Pages G. Implication of the ERK pathway on the post-transcriptional regulation of VEGF mRNA stability. Methods Mol Biol 2010; 661: 451-69.
29. Nakabayashi H, Yawata T, Shimizu K. Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer 2010; 10: 339 [Epub ahead of print].
30. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
31. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
32. Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfalvi A. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004; 117: 263-84.
33. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48: 347-56.
34. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 2006; 53: 799-808.
35. White MA, Nicolette C, Minden A et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995; 24: 533-41.
36. Young MR, Li JJ, Rincón M et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 1999; 96: 9827-32.
37. Zhu F, Zhang Z, Wu G et al. Rho kinase inhibitor fasudil suppresses migration and invasion through down-regulating the expression of VEGF in lung cancer cell line A549. Mol Oncol 2010 (in press).
38. Fukushima M, Nakamura M, Kohjima M et al. Fasudil hydrochloride, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagen activity in hepatic stella cells. Liver Int 2005; 25: 829-38.
39. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
40. Simon C, Hicks MJ, Nemechek AJ et al. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 1999; 80: 1412-9.
41. Yao J, Xiong S, Klos K et al. Mulitple pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-β1 in human breast cancer cells. Oncogene 2001; 20: 8066-74.